MEDICINA
Departamento
Karolinska University Hospital
Estocolmo, SueciaPublicaciones en colaboración con investigadores/as de Karolinska University Hospital (26)
2024
-
Antibiotics against Pseudomonas aeruginosa on Human Skin Cell Lines: Determination of the Highest Non-Cytotoxic Concentrations with Antibiofilm Capacity for Wound Healing Strategies
Pharmaceutics, Vol. 16, Núm. 1
-
Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis
Kidney International Reports
2023
-
Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry
European heart journal, Vol. 44, Núm. 35, pp. 3357-3370
2022
-
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis
npj Genomic Medicine, Vol. 7, Núm. 1
2021
-
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: A multicentre retrospective observational cohort study
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 8, pp. 2172-2181
2020
-
Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry
Revista Espanola de Cardiologia, Vol. 73, Núm. 4, pp. 313-323
-
One-year prognosis of patients with heart failure in Spain. ESC-EORP-HFA Heart Failure Long-Term Registry
REC: CardioClinics, Vol. 55, Núm. 4, pp. 207-216
2019
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1
-
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world
European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1383-1397
2017
-
Transancestral mapping and genetic load in systemic lupus erythematosus
Nature Communications, Vol. 8
2016
-
Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies
Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344
-
Off-label use of rituximab for systemic lupus erythematosus in Europe
Lupus Science and Medicine, Vol. 3, Núm. 1
-
The European guideline on management of major bleeding and coagulopathy following trauma: Fourth edition
Critical Care, Vol. 20, Núm. 1
2014
-
Identification of IL12RB1 as a Novel Systemic Sclerosis Susceptibility Locus
Arthritis and Rheumatology
2013
-
Management of bleeding and coagulopathy following major trauma: An updated European guideline
Critical Care, Vol. 17, Núm. 2
-
The STOP the Bleeding Campaign
Critical Care
2012
-
Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK
Annals of the Rheumatic Diseases, Vol. 71, Núm. 1, pp. 136-142
2011
-
The functional polymorphism 844 A>G in Fc αRI (CD89) does not contribute to systemic sclerosis or rheumatoid arthritis susceptibility
Journal of Rheumatology, Vol. 38, Núm. 3, pp. 446-449
2010
-
A 3′-untranslated region variant is associated with impaired expression of CD226 in T and natural killer T cells and is associated with susceptibility to systemic lupus erythematosus
Arthritis and Rheumatism, Vol. 62, Núm. 11, pp. 3404-3414
-
Management of bleeding following major trauma: An updated European guideline
Critical Care, Vol. 14, Núm. 2